Hisham Hashem
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hisham Hashem has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Ebraam B. Kamel
Pharmaceutical Chemistry Department, Faculty of Pharmacy Egyptian Russian University Badr City Cairo Egypt
2 shared publications - Eman A Bahgat
Zagazig University, Faculty of Pharmacy, Pharmaceutical Analytical Chemistry Department , Zagazig 44519, Egypt
2 shared publications - Hanaa Saleh
Zagazig University, Faculty of Pharmacy, Pharmaceutical Analytical Chemistry Department , Zagazig 44519, Egypt
2 shared publications - Maya S. Eissa
Pharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo 11829, Egypt
2 shared publications - Adel Ehab Ibrahim
Natural and Medical Sciences Research Center, University of Nizwa, Birkat Al Mauz, Nizwa 616, Oman
1 shared publication Magda Elhenawee
Faculty of Pharmacy, Pharmaceutical Analytical Chemistry Department, Zagazig University, Egypt
1 shared publication
Latest Publications
- 9 December 2023
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 107 (2) , 362-370
Exciting Advances in Sustainable Spectrophotometric Micro-Quantitation of an Innovative Painkiller “Tramadol and Celecoxib” Mixture in the Presence of a Toxic Impurity, Promoting Greenness and Whiteness Studies
Tramadol (TRM) and celecoxib (CLX) are a novel mixture that helps relieve impetuous, acute pain when other painkillers have no action. It is also reported that the currently studied drugs, tramadol and celecoxib, are used to control COVID-19 symptoms. The current work highlights three important pillars of modern pharmaceutical analysis, which are as follows; impurity profiling, greenness/whiteness studies and simplicity accompanied by sensitivity. Since 4-methyl acetophenone inhibits the human carbonyl reductase enzyme (type I), and since this compound may pose a health risk, it is crucial to regulate its concentration in all dosage forms of CLX. Two simple and green spectrophotometric methods were developed, namely; Third Derivative (D3) and Fourier Self Deconvulation (FSD) for resolving severely overlapped spectra of tramadol and celecoxib in the presence of 4-methyl acetophenone (4-MAP) as a process-related impurity in their novel tablet combination. The two approaches showed acceptable linearity with an excellent correlation coefficient. Simply, for both methods tramadol was measured when celecoxib and 4-methyl acetophenone were zero-crossing. The same procedure was applied for measuring celecoxib and its process-related impurity; 4-methyl acetophenone. The methodologies developed were thoroughly validated in compliance with ICH guidelines. Student t and F-tests revealed no statistically substantial variation among the current methods and the reported method. No spectrophotometric methods have been published for the simultaneous analysis of TRM and CLX along with 4-MAP. As a result, the newly developed spectrophotometric approaches hold great relevance and originality in the field of pharmaceutical analysis.
- 9 December 2023
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 107 (2) , 362-370
Exciting Advances in Sustainable Spectrophotometric Micro-Quantitation of an Innovative Painkiller “Tramadol and Celecoxib” Mixture in the Presence of a Toxic Impurity, Promoting Greenness and Whiteness Studies
Tramadol (TRM) and celecoxib (CLX) are a novel mixture that helps relieve impetuous, acute pain when other painkillers have no action. It is also reported that the currently studied drugs, tramadol and celecoxib, are used to control COVID-19 symptoms. The current work highlights three important pillars of modern pharmaceutical analysis, which are as follows; impurity profiling, greenness/whiteness studies and simplicity accompanied by sensitivity. Since 4-methyl acetophenone inhibits the human carbonyl reductase enzyme (type I), and since this compound may pose a health risk, it is crucial to regulate its concentration in all dosage forms of CLX. Two simple and green spectrophotometric methods were developed, namely; Third Derivative (D3) and Fourier Self Deconvulation (FSD) for resolving severely overlapped spectra of tramadol and celecoxib in the presence of 4-methyl acetophenone (4-MAP) as a process-related impurity in their novel tablet combination. The two approaches showed acceptable linearity with an excellent correlation coefficient. Simply, for both methods tramadol was measured when celecoxib and 4-methyl acetophenone were zero-crossing. The same procedure was applied for measuring celecoxib and its process-related impurity; 4-methyl acetophenone. The methodologies developed were thoroughly validated in compliance with ICH guidelines. Student t and F-tests revealed no statistically substantial variation among the current methods and the reported method. No spectrophotometric methods have been published for the simultaneous analysis of TRM and CLX along with 4-MAP. As a result, the newly developed spectrophotometric approaches hold great relevance and originality in the field of pharmaceutical analysis.
- 27 February 2023
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 106 (4) , 1056-1069
Manipulation and Processing of Spectral Signals for the Assay of the Newly Authorized Mixture of Bupivacaine/Meloxicam Using Fully Green Solvents and a Comparative Green Evaluation Supporting the Greenness and Sustainability of the Developed Smart Spectrophotometric Methods
Background: The bupivacaine (BVC)/meloxicam (MLX) combination is the first extended-release dual-acting local anesthetic (DALA) that provides 72 h of postoperative pain relief. It reduces opioid use after surgery and manages pain better than BVC alone over 72 h, and overcomes surgical site inflammation with a new synergistic mode of action that combines BVC with a low dosage of MLX. Objective: In today's pharmaceutical research, we take great care to only use non-toxic solvents that pose no threat to either humans or the environment. This work determines BVC and MLX simultaneously, utilizing water and 0.1 M HCl in water as solvents. Moreover, the eco-friendliness of the specified solvents and the whole method development steps was evaluated based on how user-friendly they were using four standard methodologies. Methods: The developed spectrophotometric methods depended on either zero-order, derivative, or ratio spectra that only required simple mathematical handling. The current techniques include dual wavelength (DW), Fourier self-deconvolution (FSD), first derivative (D1), ratio difference (RD), and first ratio derivative (DD1). Results: Linearity was confirmed over a concentration range of 50–700 μg/mL for BVC and 1–10 μg/mL for MLX. For BVC and MLX, the LOQs were 26.85–41.33 μg/mL and 0.21–0.95 μg/mL, while the LODs were 8.86–13.64 μg/mL and 0.06–0.31 μg/mL, respectively. For the full validation of the proposed methods, ICH (international conference on harmonization) criteria were followed. Conclusion: Current methods have the advantage of sticking to the basis of zero-order, derivative, or ratio spectra and needing just the barest minimum of data processing: no complex software, lengthy stages, or transformations are needed. Highlights: No spectrophotometric methods have been published for the simultaneous analysis of BVC and MLX. As a result, the newly developed spectrophotometric approaches have great relevance and originality in the field of pharmaceutical analysis.
- 27 February 2023
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 106 (4) , 1056-1069
Manipulation and Processing of Spectral Signals for the Assay of the Newly Authorized Mixture of Bupivacaine/Meloxicam Using Fully Green Solvents and a Comparative Green Evaluation Supporting the Greenness and Sustainability of the Developed Smart Spectrophotometric Methods
Background: The bupivacaine (BVC)/meloxicam (MLX) combination is the first extended-release dual-acting local anesthetic (DALA) that provides 72 h of postoperative pain relief. It reduces opioid use after surgery and manages pain better than BVC alone over 72 h, and overcomes surgical site inflammation with a new synergistic mode of action that combines BVC with a low dosage of MLX. Objective: In today's pharmaceutical research, we take great care to only use non-toxic solvents that pose no threat to either humans or the environment. This work determines BVC and MLX simultaneously, utilizing water and 0.1 M HCl in water as solvents. Moreover, the eco-friendliness of the specified solvents and the whole method development steps was evaluated based on how user-friendly they were using four standard methodologies. Methods: The developed spectrophotometric methods depended on either zero-order, derivative, or ratio spectra that only required simple mathematical handling. The current techniques include dual wavelength (DW), Fourier self-deconvolution (FSD), first derivative (D1), ratio difference (RD), and first ratio derivative (DD1). Results: Linearity was confirmed over a concentration range of 50–700 μg/mL for BVC and 1–10 μg/mL for MLX. For BVC and MLX, the LOQs were 26.85–41.33 μg/mL and 0.21–0.95 μg/mL, while the LODs were 8.86–13.64 μg/mL and 0.06–0.31 μg/mL, respectively. For the full validation of the proposed methods, ICH (international conference on harmonization) criteria were followed. Conclusion: Current methods have the advantage of sticking to the basis of zero-order, derivative, or ratio spectra and needing just the barest minimum of data processing: no complex software, lengthy stages, or transformations are needed. Highlights: No spectrophotometric methods have been published for the simultaneous analysis of BVC and MLX. As a result, the newly developed spectrophotometric approaches have great relevance and originality in the field of pharmaceutical analysis.
- Open Access
- 1 February 2017
- Published by Scientific Scholar in Arabian Journal of Chemistry
- Vol. 10, S35-S41
A rapid stability indicating LC-method for determination of praziquantel in presence of its pharmacopoeial impurities
This study reports for the first time about a stability indicating RP-HPLC method for quantitative determination of Praziquantel (PZQ) in bulk powder and dosage form and in presence of its pharmacopoeial impurities. The chromatographic separation was carried out on (Caltrex AI®) calixarene column, a relatively new packing material. Chromatography was done using an isocratic binary mobile phase consisting of ACN and 25mM ammonium acetate (NH4Ac) in the ratio of 40:60 at flow rate of 1mLmin−1, 30°C and 210nm wavelength for detection. The elution time of PZQ was found to be 6.15±0.03min. The method was validated for system suitability, linearity, precision, limits of detection and quantitation, specificity, stability and robustness. The robustness study was done for small changes in temperature, flow rate, wavelength of detection and % of ACN in mobile phase. Stability tests were done through exposure of the analyte solution to five different stress conditions: Reflux with 1N HCl, reflux with 1N NaOH, reflux with 30% H2O2, thermal degradation of powder and exposure to UV radiation. Limits of detection and quantification were found to be 0.56 and 1.70μgmL−1, respectively. The recovery value of this method was 100.30%±1.10 and the reproducibility was within 1.31
- 1 February 2017
- Published by Scientific Scholar in Arabian Journal of Chemistry
- Vol. 10, S35-S41
Open AccessA rapid stability indicating LC-method for determination of praziquantel in presence of its pharmacopoeial impurities
This study reports for the first time about a stability indicating RP-HPLC method for quantitative determination of Praziquantel (PZQ) in bulk powder and dosage form and in presence of its pharmacopoeial impurities. The chromatographic separation was carried out on (Caltrex AI®) calixarene column, a relatively new packing material. Chromatography was done using an isocratic binary mobile phase consisting of ACN and 25mM ammonium acetate (NH4Ac) in the ratio of 40:60 at flow rate of 1mLmin−1, 30°C and 210nm wavelength for detection. The elution time of PZQ was found to be 6.15±0.03min. The method was validated for system suitability, linearity, precision, limits of detection and quantitation, specificity, stability and robustness. The robustness study was done for small changes in temperature, flow rate, wavelength of detection and % of ACN in mobile phase. Stability tests were done through exposure of the analyte solution to five different stress conditions: Reflux with 1N HCl, reflux with 1N NaOH, reflux with 30% H2O2, thermal degradation of powder and exposure to UV radiation. Limits of detection and quantification were found to be 0.56 and 1.70μgmL−1, respectively. The recovery value of this method was 100.30%±1.10 and the reproducibility was within 1.31